The number of genes tested for ovarian and breast cancer has grown, but most patients do not undergo testing, and variant-of-unknown-significance results are common, especially among minority populations.
Investigators evaluated the clinical benefits of sequential chemoradiation (SCRT), concurrent chemoradiation (CCRT), and radiation alone (RT) as postoperative adjuvant treatments in early-stage cervical cancer.
The cases were incidentally identified during a next-generation sequencing (NGS) analysis of matched normal and tumor tissue for a hospital-based prospective study.
Investigators of the observational study sought to clarify the time-dependent effects between long-term oral contraceptive use and risk for breast, ovarian, and endometrial cancer risk.
Patients with advanced or recurrent endometrial cancer enrolled in the experimental arm will receive atezolizumab in combination with paclitaxel and carboplatin.
Quality-adjusted progression-free survival (QA-PFS) represents an adjustment to PFS that incorporates patient-reported toxicity and other detrimental effects of treatment.
